What are the earliest signs of Parkinson's, years before a tremor?

Which symptoms appear years before a tremor starts?

A reduced sense of smell, constipation, depression, and acting out dreams are the earliest recognised signs of Parkinson's. These non-motor symptoms, which are changes that do not affect physical movement, can predate classic motor symptoms by years. However, because these symptoms are incredibly common in the general public, a single symptom on its own rarely provides a certain prediction.

Specific statistical risk rates vary widely between these early signs. A meta-analysis of seven prospective studies tracking 3,272 people with hyposmia, which is a reduced sense of smell, showed they had a 3.84-fold risk of developing Parkinson's. For constipation, a meta-analysis of nine studies with 741,593 participants reported a pooled odds ratio of 2.27, while a larger review of 17 studies with 3,024,193 participants found a ratio of 2.36.

Mental health and sleep changes add to this risk picture but are not specific to Parkinson's. A meta-analysis of 15 studies showed that people with prodromal depression, which is depression occurring before obvious disease signs emerge, are about twice as likely to develop the disease. Additionally, a study of 1,280 patients with REM sleep behaviour disorder, which is a sleep condition where people act out their dreams, found a 6.25% annual rate of transition to a neurological disease, though 43.5% of those who converted developed dementia first rather than parkinsonism.

Why do researchers focus so heavily on acting out dreams?

REM sleep behaviour disorder is a sleep condition where the body loses its normal muscle paralysis, causing people to physically act out their dreams. Researchers focus heavily on this because it is the strongest known predictor of future brain disease. Over time, the vast majority of people with this sleep disorder develop a neurodegenerative condition, with one systematic review showing that only 3.4% of patients remain healthy after 14 years.

Tracking studies show how the risk of developing a brain disease increases year by year. A multicentre study followed 1,280 patients with laboratory-confirmed sleep disorders who had no motor or cognitive signs at the start. The estimated risk of developing a neurodegenerative condition was 10.6% after two years, 31.3% after five years, and 73.5% after 12 years.

While the connection is strong, this sleep disorder does not guarantee a future Parkinson's diagnosis. Among the 352 patients who converted to a disease in the multicentre study, 199 developed parkinsonism, but 153 developed dementia first. Across a separate systematic review of longitudinal studies, 43% of these sleep patients eventually developed Parkinson's disease, while 25% developed dementia with Lewy bodies, which is a type of progressive dementia.

Does losing your sense of smell or chronic constipation mean you are developing Parkinson's?

The vast majority of people with a reduced sense of smell or chronic constipation will never develop Parkinson's disease. While these symptoms are common in people who eventually get diagnosed, they are also highly prevalent in the general population. Because Parkinson's only affects about 1% of people over the age of 60, having these symptoms only marginally increases your absolute risk.

A reduced sense of smell increases risk but is a weak predictor on its own. A meta-analysis of seven prospective studies tracked 3,272 people with a reduced sense of smell over 3 to 17 years. Only 176 participants, which is about 5.4%, actually developed Parkinson's, showing that smell tests cannot reliably isolate the disease because smell loss is also common in normal ageing.

Constipation is even more common and less specific than smell loss. In a cohort of 9,396 community volunteers aged 50 and older, 21% of women and 13% of men reported constipation, which is a rate far higher than the prevalence of Parkinson's. A meta-analysis of 17 studies with 3,024,193 participants reported a 2.36-fold increased risk of developing Parkinson's in constipated individuals, but this analysis was weakened by high statistical heterogeneity, meaning the underlying study results varied wildly.

How many years before motor symptoms do these changes usually emerge?

The early phase of Parkinson's can stretch across several decades before classic motor symptoms appear. Constipation is typically the earliest sign, appearing up to 20 years before diagnosis. In a meta-analysis of nine studies with 741,593 participants, the risk of developing Parkinson's was 2.13 times higher even when constipation was assessed more than 10 years before diagnosis, driven by gut transit times slowing from 12 hours to as much as 168 hours.

Other physical and sensory changes emerge closer to the onset of motor symptoms. A systematic review of seven prospective studies showed that a reduced sense of smell is associated with a 3.84-fold increased risk of Parkinson's, with one tracking study of male participants showing this loss occurs at least four years before diagnosis. Low blood pressure upon standing is another early sign; a trial registration for a natural history study, which is a record of a study before it is run rather than peer-reviewed results, notes that most patients with standing low blood pressure develop motor or cognitive signs within five years.

Sleep disturbances are typically among the final changes to emerge before a diagnosis. A meta-analysis examining the timing of REM sleep behaviour disorder found that 38% of patients who developed Parkinson's did so at a mean of 3.5 years after being diagnosed with the sleep disorder.

Can medical tests tell whether these early signs are definitely Parkinson's?

Modern brain scans and biological tests can detect Parkinson's biology early, but they cannot show how the disease will progress. A DaTscan, which is an imaging test measuring dopamine transporter density in the brain, can confirm dopamine system damage but cannot predict when symptoms will start or how severe they will be. Additionally, between 4% and 15% of patients diagnosed with Parkinson's have entirely normal scans, a phenomenon known as scans without evidence of dopaminergic deficit.

Protein tests offer high accuracy but still miss some cases. An alpha-synuclein seed amplification assay, which is a lab test that multiplies trace amounts of abnormal proteins, can find clusters in spinal fluid or skin. A systematic review of 36 studies with 2,722 patients and 2,278 controls found this test has a combined sensitivity of 88% and specificity of 95%. A preprint, which must be treated as a preliminary report because it is not peer-reviewed, also described a blood-based approach, but even these biological tests are not perfect; in a phase 1 trial of a new immunotherapy, one of 20 patients still tested negative.

No available test can help slow down or stop the disease. There is currently no treatment proven to alter the underlying brain degeneration, meaning early detection cannot prevent the disease from worsening. Furthermore, a DaTscan cannot reliably tell Parkinson's apart from other progressive conditions like multiple system atrophy or progressive supranuclear palsy.

What this does not show

Clinical evidence does not support several widely held beliefs about early indicators or early treatments. Long-standing essential tremor does not reliably signal early Parkinson's. The TITAN study, which is a preprint that has not yet been peer-reviewed, followed 599 essential tremor patients and found that only 1.0% met the criteria for early Parkinson's. Furthermore, mild motor changes in older adults are often caused by vascular or Alzheimer's pathology rather than Parkinson's; when researchers tracked 50 patients with early motor symptoms but normal brain scans, only 13 actually had Parkinson's, while 37 had other diseases.

Every major clinical trial of early-stage, disease-modifying therapies has failed. The phase 2 SPARK trial of cinpanemab in 357 participants was terminated early for lack of clinical benefit. The phase 2 PASADENA trial of prasinezumab in 316 participants and the phase 2b PADOVA trial in 586 participants also failed to meet their primary clinical endpoints, though the drug is still being evaluated in PARAISO, which is a registered phase 3 trial that has not yet reported results. Similarly, a phase 2 trial of NLY01 in 255 participants and a phase 3 trial of preladenant in 1,007 participants found no superiority over placebo. A futility trial of simvastatin in 235 patients showed the drug was futile, with the treated group actually worsening by an additional 1.52 points.

Several high-profile claims about early-stage interventions rest on retracted research. A clinical trial of 60 patients claiming that a 12-week course of probiotics improved motor scores was retracted. A trial of 160 patients evaluating pramipexole and levodopa was also retracted. Finally, a genomic screen of 755 early-onset patients published as a preprint was retracted.

This overview provides you with the exact numbers and trial outcomes to help you understand the limitations of early signs and testing. You can use these facts to guide a structured conversation with a specialist about your specific symptom patterns and overall brain health.